Cargando…

Risk of cancer in patients with fecal incontinence

BACKGROUND: Fecal incontinence may be an early symptom of cancer, but its association with cancer remains unclear. We examined the risk of selected cancers, including colorectal cancer, other gastrointestinal cancers, hormone‐related cancers, and lymphoma, in patients with fecal incontinence. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Adelborg, Kasper, Veres, Katalin, Sundbøll, Jens, Gregersen, Hans, Sørensen, Henrik Toft
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797632/
https://www.ncbi.nlm.nih.gov/pubmed/31468727
http://dx.doi.org/10.1002/cam4.2509
_version_ 1783459872307675136
author Adelborg, Kasper
Veres, Katalin
Sundbøll, Jens
Gregersen, Hans
Sørensen, Henrik Toft
author_facet Adelborg, Kasper
Veres, Katalin
Sundbøll, Jens
Gregersen, Hans
Sørensen, Henrik Toft
author_sort Adelborg, Kasper
collection PubMed
description BACKGROUND: Fecal incontinence may be an early symptom of cancer, but its association with cancer remains unclear. We examined the risk of selected cancers, including colorectal cancer, other gastrointestinal cancers, hormone‐related cancers, and lymphoma, in patients with fecal incontinence. METHODS: Using Danish population‐based registries, all patients with hospital‐based diagnoses of fecal incontinence during 1995‐2013 were identified. We calculated cumulative incidences of cancers. As a measure of relative risks, we computed standardized incidence ratios (SIRs), that is, the observed number of cancers relative to the expected number based on national incidence rates by sex, age, and calendar year. RESULTS: Among 16 556 patients with fecal incontinence, the cumulative incidence of colorectal cancers, other gastrointestinal cancers, hormone‐related cancers, and lymphoma each was less than 0.4% after 1 year. It increased to under 3% after 10 years. The SIR for any cancer during 19 years of follow‐up was 1.12 [95% confidence interval (CI), 1.06‐1.19]. The SIRs during the first year were 2.31 (95% CI, 1.65‐3.13) for colorectal cancer, 1.56 (95% CI, 0.89‐2.54) for other gastrointestinal cancers, 1.00 (95% CI, 0.72‐1.35) for hormone‐related cancers, and 2.02 (95% CI, 1.01‐3.61) for lymphoma. Beyond 1 year, the SIR reached unity for other gastrointestinal cancers, hormone‐related cancers, and lymphoma, while a reduced risk was observed for colorectal cancer (SIR = 0.77, 95% CI, 0.59‐0.98). CONCLUSIONS: Fecal incontinence was a marker of cancer, especially gastrointestinal cancers and lymphoma within 1 year, which presumably is driven partly by reverse causation. However, the absolute risks were low. Heightened diagnostic efforts may explain in part the increased short‐term risk of colorectal cancers.
format Online
Article
Text
id pubmed-6797632
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67976322019-10-21 Risk of cancer in patients with fecal incontinence Adelborg, Kasper Veres, Katalin Sundbøll, Jens Gregersen, Hans Sørensen, Henrik Toft Cancer Med Cancer Prevention BACKGROUND: Fecal incontinence may be an early symptom of cancer, but its association with cancer remains unclear. We examined the risk of selected cancers, including colorectal cancer, other gastrointestinal cancers, hormone‐related cancers, and lymphoma, in patients with fecal incontinence. METHODS: Using Danish population‐based registries, all patients with hospital‐based diagnoses of fecal incontinence during 1995‐2013 were identified. We calculated cumulative incidences of cancers. As a measure of relative risks, we computed standardized incidence ratios (SIRs), that is, the observed number of cancers relative to the expected number based on national incidence rates by sex, age, and calendar year. RESULTS: Among 16 556 patients with fecal incontinence, the cumulative incidence of colorectal cancers, other gastrointestinal cancers, hormone‐related cancers, and lymphoma each was less than 0.4% after 1 year. It increased to under 3% after 10 years. The SIR for any cancer during 19 years of follow‐up was 1.12 [95% confidence interval (CI), 1.06‐1.19]. The SIRs during the first year were 2.31 (95% CI, 1.65‐3.13) for colorectal cancer, 1.56 (95% CI, 0.89‐2.54) for other gastrointestinal cancers, 1.00 (95% CI, 0.72‐1.35) for hormone‐related cancers, and 2.02 (95% CI, 1.01‐3.61) for lymphoma. Beyond 1 year, the SIR reached unity for other gastrointestinal cancers, hormone‐related cancers, and lymphoma, while a reduced risk was observed for colorectal cancer (SIR = 0.77, 95% CI, 0.59‐0.98). CONCLUSIONS: Fecal incontinence was a marker of cancer, especially gastrointestinal cancers and lymphoma within 1 year, which presumably is driven partly by reverse causation. However, the absolute risks were low. Heightened diagnostic efforts may explain in part the increased short‐term risk of colorectal cancers. John Wiley and Sons Inc. 2019-08-29 /pmc/articles/PMC6797632/ /pubmed/31468727 http://dx.doi.org/10.1002/cam4.2509 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Prevention
Adelborg, Kasper
Veres, Katalin
Sundbøll, Jens
Gregersen, Hans
Sørensen, Henrik Toft
Risk of cancer in patients with fecal incontinence
title Risk of cancer in patients with fecal incontinence
title_full Risk of cancer in patients with fecal incontinence
title_fullStr Risk of cancer in patients with fecal incontinence
title_full_unstemmed Risk of cancer in patients with fecal incontinence
title_short Risk of cancer in patients with fecal incontinence
title_sort risk of cancer in patients with fecal incontinence
topic Cancer Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797632/
https://www.ncbi.nlm.nih.gov/pubmed/31468727
http://dx.doi.org/10.1002/cam4.2509
work_keys_str_mv AT adelborgkasper riskofcancerinpatientswithfecalincontinence
AT vereskatalin riskofcancerinpatientswithfecalincontinence
AT sundbølljens riskofcancerinpatientswithfecalincontinence
AT gregersenhans riskofcancerinpatientswithfecalincontinence
AT sørensenhenriktoft riskofcancerinpatientswithfecalincontinence